Needham Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
In a report released today, Joseph Stringer from Needham reiterated a Buy rating on Alnylam Pharma (ALNY), with a price target of $180.00. The company’s shares closed last Thursday at $140.87.
According to TipRanks.com, Stringer has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.9% and a 38.1% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Lexicon Pharmaceuticals, and Phathom Pharmaceuticals.
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $171.67, representing a 18.4% upside. In a report issued on April 20, Chardan Capital also reiterated a Buy rating on the stock with a $190.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $178.41 and a one-year low of $119.29. Currently, Alnylam Pharma has an average volume of 555.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Read More on ALNY: